Amgen Inc (AMGN) stock
Close on Nov 12, 2026Market cap $252.51BP/E 27.1Yield 2.07%
Amgen Inc grew revenue 8.2% to $38.90B over the twelve months to Sep 30, 2026. Operating income rose 45.4% to $12.61B, moving the operating margin from 24.1% to 32.4%. Free cash flow was $9.58B, down 17.0% from a year earlier. At the latest close the market valued the company at $252.51B, 27.1 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $252.51B
- P/E ratio
- 27.1
- Price to sales
- 6.49
- Price to book
- 17.59
- Dividend yield
- 2.07%
- Free cash flow yield
- 3.79%
Fundamentals
- Revenue
- $38.90B
- Net income
- $9.39B
- EPS, diluted
- $17.25
- Free cash flow
- $9.58B
- Book value per share
- $26.29
- Diluted shares
- 546M
Trading
- Next earnings
- Feb 2, 2027 (estimated, during market hours)
- Previous close
- $468.11
- Open
- $471.86
- Day's range
- $466.92 – $474.00
- Volume
- 2,827,908
- Average volume (20 days)
- 2,720,012
- Index membership
- S&P 500, Nasdaq-100, Dow Jones Industrial Average (since Aug 2020), Russell 1000, Russell 3000
- Beta (5 years)
- 0.41
- 52-week range
- $312.38 – $483.99
- RSI (14 days)
- 62.9
- Volatility (1 year)
- 28.7%
- Relative volume
- 1.04×
- WACC
- 6.8%
Index membership is inferred from the holdings of funds that track each index (VOO, IVV, SPYM, QQQ, UDOW, DDM, IWB, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2009, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | AMGN | S&P 500 | Difference | AMGN per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +11.9% | -2.7% | +14.5 pts | ||
| 3 months | +12.9% | -1.7% | +14.6 pts | ||
| Year to date | +45.6% | +11.9% | +33.7 pts | ||
| 1 year | +42.7% | +12.0% | +30.8 pts | ||
| 3 years | +91.2% | +78.2% | +13.0 pts | +24.1% | +21.2% |
| 5 years | +158.1% | +73.2% | +84.9 pts | +20.9% | +11.6% |
| 10 years | +322.3% | +309.6% | +12.6 pts | +15.5% | +15.1% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Amgen filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Results
About Amgen
Biological Products, (No Diagnostic Substances)
The company operates in the biotechnology and pharmaceutical sector, focusing on the discovery, development, and delivery of innovative therapies. Its primary offerings include treatments such as Prolia, Repatha, Otezla, Enbrel, Evenity, Xgeva, Tepezza, Blincyto, Nplate, Tezspire, Kyprolis, Aranesp, Krystexxa, and Vectibix. Revenue is predominantly derived through a specialized product segment alongside related technology rights and collaborative agreements. The enterprise serves patients and healthcare institutions, directing sales largely through major regional distribution networks and wholesale customers.
Company profile, executives and historyAmgen stock: common questions
What is Amgen's stock price?
AMGN closed at $467.06 on Nov 12, 2026, down 0.22% on the day. Over the past 52 weeks it traded between $312.38 and $483.99.
What is Amgen's market cap?
Amgen was worth $252.51B at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is AMGN's P/E ratio?
AMGN trades at 27.1 times earnings, based on diluted earnings per share of $17.25 over the twelve months to Sep 30, 2026.
How much revenue does Amgen make?
Amgen reported revenue of $38.90B for the twelve months to Sep 30, 2026, up 8.2% from a year earlier.
Does Amgen pay a dividend?
Yes. Amgen paid $9.66 per share over the last twelve months, a yield of 2.07% at the latest price, and has raised its annual dividend 9 years in a row.
When does Amgen report earnings next?
Amgen is expected to report Q4 FY2026 results on Feb 2, 2027, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has AMGN stock performed over the past year?
Including dividends, AMGN returned +42.7% over the past year, against +12.0% for the S&P 500.
How many AMGN shares are sold short?
13M shares were sold short at the latest FINRA report, 2.33% of the float, or 5.0 days of average trading volume.
Who are Amgen's competitors?
Companies most similar to Amgen by business, industry and size include GILD, BMY, PFE, BIIB, ABBV.
See a number that looks wrong?